10 results about "Virus vaccine" patented technology

The present disclosure provides a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a liposomal adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the liposomal adjuvant.

The present application relates to an avian cell line capable of supporting viral growth of Marek's Disease Virus (MDV), including Herpes Virus of Turkeys (HVT), methods of producing such cell lines, and therapeutic uses of the cell lines and resulting vaccines.

The application provides a KRT31 gene knockout cell line and its application in promoting replication of viruses of the Picornaviridae family and / or production of vaccines of viruses of the Picornaviridae family, and belongs to the technical field of genetic engineering. The application provides an application of a KRT31 gene or a coded protein thereof as a target in preparation of a product for regulating replication of viruses of the Picornaviridae family and / or vaccine production. Up-regulation of the expression level of the KRT31 gene can inhibit replication of viruses of the Picornaviridae family, and down-regulation of the expression level of the KRT31 gene can promote replication of viruses of the Picornaviridae family. The application adopts sgRNA to knockout the KRT31 gene to prepare a cell line with lost function of a gene coded protein, so as to promote replication of viruses of the Picornaviridae family, improve virus titer and antigen yield, and help to efficiently prepare vaccines of viruses of the Picornaviridae family.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition, a preparation method and application thereof. Specifically, based on the theory of traditional Chinese veterinary medicine of'strengthening the body resistance and eliminating pathogenic factors, and treating the root and branch', aiming at the pathogenesis of 'deficiency in the root and excess in the branch' of low immunity in animals, eight kinds of medicinal materials are scientifically screened to form a traditional Chinese medicine compound with the effects of tonifying qi and nourishing blood, invigorating the spleen and kidney, dredging collaterals and eliminating dampness, and clearing heat and detoxifying. Through the verification of a cyclophosphamide-induced low immunity mouse model, the traditional Chinese medicine composition can significantly improve the mental state of the mice, restore the body weight and thymus / spleen index, repair the pathological damage of the spleen tissue, and adjust the inflammatory factor level in the serum and spleen tissue. In addition, in a Marek's disease virus infection model, the traditional Chinese medicine composition combined with the Marek's disease virus vaccine can significantly reduce the viral load in the peripheral blood, liver and spleen, and reduce the liver enlargement, hemorrhage and microscopic structure damage, showing a good immune synergistic effect.

The application discloses a Plectropomus leopardus spleen cell line and application thereof. Plectropomus leopardus The spleen cell line PLS has a preservation number of GDMCC No: 68131. The PLS is obtained through primary culture and multiple subculture, has a fast cell growth speed, has been stably subcultured for more than 60 generations, has good activity after cryopreservation, and lays a foundation for Plectropomus leopardus gene germplasm resource preservation. Meanwhile, the PLS is sensitive to fish nervous necrosis virus and iridovirus, can be applied to exogenous gene function research, fish virus isolation, virus infection pathogenesis, virus host interaction and virus in-vitro infection model, and provides a high-efficiency amplification system for Plectropomus leopardus virus vaccine preparation.

This invention relates to an EV71 virus mRNA vaccine and its application, wherein the EV71 virus mRNA vaccine contains an encoding EV71 virus. vp1 The mRNA molecule of the gene is encapsulated by lipid nanoparticles; the nucleic acid sequence of the mRNA molecule is shown in SEQ ID NO.1; the sequence encoding the amino acids of the mRNA molecule is shown in SEQ ID NO.2. The mRNA vaccine provided by this invention significantly enhances the production of anti-EV71 virus in mice. vp1 Neutralizing antibody titers and specific cellular immune responses.

The present disclosure provides, a vaccine composition that comprises an Epstein Barr Virus (EBV) polypeptide and a squalene nanoemulsion (SNE) adjuvant, and methods of inducing an immune response to an Epstein Barr Virus (EBV) or methods of preventing infection of or reducing the likelihood of infection by an Epstein Barr Virus (EBV) using the compositions, or a combination of the EBV polypeptide and the SNE adjuvant.

The present invention relates to an NP antigen peptide of the SFTS virus, the NP antigen peptide including a novel mutation. NP protein sequences of 56 strains collected from the entire genotype were analyzed, consensus sequences of NP proteins were derived therefrom, and then an NP peptide antigen incorporating an amino acid substitution mutation and having improved structural stability was designed through structural analysis modeling. As a result of evaluating immunogenicity and protective ability using an SFTS virus vaccine composition prepared using the NP peptide antigen, it was found that a vaccine composition comprising the NP antigen of the present invention has an excellent ability to produce an immune response and an excellent ability to protect against SFTS virus infection, and thus the NP antigen peptide according to the present invention can be used in a vaccine composition for severe fever with thrombocytopenia syndrome.

This invention belongs to the field of molecular biology, specifically relating to the application of SND1-overexpressing cells in promoting small RNA virus replication. The invention first constructs an SND1 gene overexpression vector, transfects it into BHK-21 cells, and then selects a stable cell line. Infection of the cell line with foot-and-mouth disease virus (FMDV) and Seneca virus (SVV) revealed that the titers of FMDV and SVV, as well as the expression levels of viral RNA and proteins, were significantly higher than in wild-type cells, indicating that SND1 promotes FMDV and SVV replication. The constructed SND1-overexpressing cells can efficiently proliferate FMDV and SVV and can be used as cell lines for FMDV and Seneca virus vaccine production. This provides a new tool for FMDV and SVV mechanism research, vaccine preparation, and the development of detection reagents, and has significant scientific research and application value.

This invention belongs to the field of biomedical technology and discloses a grouper neuronecrosis virus (NNV) vaccine, its preparation method, and its application. The invention connects the dominant NNV epitope CP4, the small molecule penetrating peptide LMWP, and grouper ferritin via a linker sequence to obtain a fusion gene fragment LCF. A recombinant expression vector is constructed based on the pET28a plasmid and expressed in *E. coli* to obtain the recombinant fusion protein rLCF. This protein aggregates and self-assembles into a nanocage-like structure based on its own characteristics, thus obtaining an NNV self-assembled vaccine. The NNV self-assembled vaccine can significantly enhance the level of specific serum antibodies and non-specific enzyme activity in grouper through immersion immunization and provides good protection after grouper infection with neuronecrosis virus (NNV), providing an important reference for the immunoprevention and control of this virus.